BioSpace News Archive

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that new data from the Phase 1 OPTIC study of ADVM-022 (AAV.7m8-aflibercept) in wet age-related macular degeneration (wet AMD) will be presented during The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinical studies in the U.S. on the combination therapy of ImmVira’s MVR-T3011 IT and Roche’s MEK inhibitor cobimetinib, to evaluate the safety and efficacy of this combo strategy.

BioSig Technologies, Inc. today announced that the Company would be exhibiting at Heart Rhythm 2022, due to take place on April 29 – May 1, 2022 at the Moscone Center in San Francisco, CA.

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing.

Therapeutic Solutions International announced today data demonstrating its JadiCell™ adult stem cell product induces multiplication of specific lung cells which are believed to give rise to new lung tissue which compensate for damaged cells.

Ambu continues to advance the market for single-use endoscopy by addressing Fibreoptic Endoscopic Evaluation of Swallowing.

Captivate Bio, a scientific solutions provider, announced that it has expanded its portfolio of cell culture solutions to include new classical media along with custom media manufacturing services and its new CET Cocktail, a kit of small molecule compounds that can be safely used in research and regenerative medicine applications to greatly improve the human pluripotent stem cell (hPSC) workflow.

The global unicompartmental knee prosthesis market is expected to reach valuation US$ 1.3 Bn by the end of 2031 and is estimated to expand at a CAGR of 3.5% from 2021 to 2031.

atai Life Sciences N.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in April.

CS Genetics, a privately held genomics-technology company, announced the appointment of Chad Geringer as Vice President of Global Sales.